Paying users zone. Data is hidden behind: .
Get 1-month access to Regeneron Pharmaceuticals Inc. for $13.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Regeneron Pharmaceuticals Inc. pages available today for free:
Common-Size Income Statement
Quarterly Data
Regeneron Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)
Based on: 10-K (filing date: 2021-02-08), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05).
Income statement item | Description | The company |
---|---|---|
Income from operations | The net result for the period of deducting operating expenses from operating revenues. | Regeneron Pharmaceuticals Inc.’s income from operations as a percentage of revenues increased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020. |
Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Regeneron Pharmaceuticals Inc.’s income before income taxes as a percentage of revenues decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |
Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Regeneron Pharmaceuticals Inc.’s net income as a percentage of revenues decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level. |